The SGO and ASCO have released a clinical guideline on neoadjuvant chemotherapy for newly diagnosed advanced ovarian cancer. Among its recommendations:

• All women with suspected stage IIIC or IV invasive epithelial ovarian cancer should be evaluated by a gynecologic oncologist before starting therapy.

• The primary clinical evaluation should include a CT of the abdomen, pelvis, and chest.

• Women with a high perioperative risk profile or a low likelihood of achieving cytoreduction to <1 cm of residual disease should receive neoadjuvant chemotherapy.

• Women who are fit for primary cytoreductive surgery, and with potentially resectable disease, may receive either neoadjuvant chemotherapy or primary cytoreductive surgery; the latter is preferred if there is a high likelihood of achieving cytoreduction to <1 cm with acceptable morbidity.

• Before neoadjuvant chemotherapy is delivered, all patients should have confirmation of an invasive ovarian, fallopian tube, or peritoneal cancer.